Our Pricing

What Are Wegovy Injections and How Do They Work for Weight Loss?

Published on: June 03, 2026

Wegovy injections are a prescription-only semaglutide treatment licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related health conditions. As a GLP-1 receptor agonist, Wegovy works by mimicking a natural hormone that regulates appetite and food intake, helping patients achieve significant weight loss when combined with a reduced-calorie diet and increased physical activity. At Cured Pharmacy, Wegovy injections are available from £124.99 following a free online consultation with our UK-registered clinical team, led by superintendent pharmacist Tarun Kumar (GPhC 2233073).

How Wegovy Injections Support Weight Loss

Wegovy injections contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that works on multiple pathways to reduce body weight. The medication slows gastric emptying, which prolongs the feeling of fullness after meals, and acts on appetite centres in the brain to reduce hunger signals [1]. In the landmark STEP clinical trial programme, participants using Wegovy injections achieved an average weight loss of 15-17% of their initial body weight over 68 weeks, compared to 2-3% with placebo [2].

The injection is administered once weekly using a pre-filled pen device, allowing patients to self-inject subcutaneously in the abdomen, thigh, or upper arm. Wegovy follows a gradual dose escalation schedule, starting at 0.25mg weekly and increasing every four weeks to the maintenance dose of 2.4mg weekly. This titration approach minimises gastrointestinal side effects while allowing the body to adjust to the medication [3]. All Wegovy injections dispensed by Cured Pharmacy are genuine UK-licensed medicines, and treatment requires approval from our UK-registered prescribers following a clinical assessment.

Wegovy Injection Dosing Schedule and Administration

The Wegovy injection dosing protocol follows a structured 16-week escalation phase designed to improve tolerability. Patients begin with 0.25mg once weekly for four weeks, then progress to 0.5mg, 1mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly [1]. Each dose is maintained for at least four weeks before advancing, and prescribers may extend any dose level if patients experience persistent side effects.

Administering Wegovy injections is straightforward with the pre-filled pen device. Patients select a consistent day each week for their injection, which can be given at any time regardless of meals. The injection site should be rotated between the abdomen, thigh, and upper arm to reduce the risk of lipodystrophy. If a dose is missed, it should be administered as soon as possible within five days; if more than five days have passed, the missed dose should be skipped and the regular schedule resumed [3].

Storage and Handling of Wegovy Injection Pens

Wegovy injections must be stored in a refrigerator at 2-8°C before first use and protected from light. Once in use, the pen can be kept at room temperature (below 30°C) or continued in the refrigerator for up to 28 days. The pen cap should be replaced after each injection to protect the medication from light. Patients should inspect the solution before each injection—it should be clear and colourless or slightly yellow, with no visible particles [4].

Clinical Evidence for Wegovy Injections

The efficacy of Wegovy injections has been demonstrated across the comprehensive STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme, which enrolled over 4,500 participants. In STEP 1, adults with obesity or overweight with comorbidities who received Wegovy injections achieved a mean weight loss of 14.9% at 68 weeks, with 86.4% of participants losing at least 5% of their body weight [2]. These results significantly exceeded the placebo group, where mean weight loss was 2.4%.

Beyond weight reduction, Wegovy injections produced meaningful improvements in cardiometabolic risk factors. Participants experienced reductions in waist circumference, systolic blood pressure, HbA1c levels in those with prediabetes, and improvements in lipid profiles [2]. The STEP 5 trial demonstrated sustained weight loss over two years of continuous treatment, with participants maintaining an average 15.2% reduction from baseline body weight [5]. These long-term data support Wegovy as an effective option for chronic weight management when used as part of a comprehensive lifestyle intervention programme.

Weight Loss Outcomes in Real-World Practice

While clinical trial results for Wegovy injections are impressive, real-world outcomes can vary based on individual factors including baseline BMI, adherence to lifestyle modifications, and metabolic health status. Patients who combine Wegovy with structured dietary changes and regular physical activity typically achieve optimal results. At Cured Pharmacy, our clinical team provides ongoing support to help patients maximise treatment outcomes, with follow-up consultations available to monitor progress and adjust treatment plans as needed.

Common Side Effects of Wegovy Injections

Like all GLP-1 receptor agonists, Wegovy injections are associated with gastrointestinal side effects, particularly during the dose escalation phase. The most commonly reported adverse effects include nausea (affecting up to 44% of patients), diarrhoea, vomiting, constipation, and abdominal pain [1]. These symptoms are typically mild to moderate in severity and tend to diminish as treatment continues and the body adapts to the medication.

To minimise gastrointestinal side effects with Wegovy injections, patients should eat smaller, more frequent meals, avoid high-fat foods, and stay well-hydrated. The gradual dose escalation schedule is specifically designed to improve tolerability. Serious side effects are rare but can include pancreatitis, gallbladder disease, and hypoglycaemia when used with other glucose-lowering medications [3]. Patients should be counselled to seek immediate medical attention if they experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction. All Wegovy prescriptions from Cured Pharmacy include comprehensive patient information leaflets and access to pharmacist support.

Who Can Use Wegovy Injections in the UK

Wegovy injections are licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [4]. NICE guidance supports the use of semaglutide 2.4mg for weight management in this population when prescribed alongside a reduced-calorie diet and increased physical activity as part of a specialist weight management service.

Wegovy injections are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The medication should be used with caution in patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy [1]. At Cured Pharmacy, every patient completes a thorough online medical assessment reviewed by our UK-registered prescribers, ensuring Wegovy is clinically appropriate and safe before dispensing. Treatment is not suitable during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment.

Wegovy Injections vs Other Weight Loss Treatments

Compared to other weight loss medications available in the UK, Wegovy injections demonstrate superior efficacy in clinical trials. While orlistat (a lipase inhibitor) typically produces 5-10% weight loss and liraglutide 3mg achieves approximately 8-12% reduction, Wegovy's average 15-17% weight loss represents a significant advancement in pharmacological obesity treatment [2][5]. However, the choice of treatment depends on individual patient factors, preferences, contraindications, and cost considerations, all of which are discussed during the clinical consultation at Cured Pharmacy.

Purchasing Wegovy Injections from Cured Pharmacy

At Cured Pharmacy, Wegovy injections are available from £124.99 with transparent upfront pricing displayed before your consultation. As a GPhC-registered online pharmacy (registration number 9012511), we provide a fully regulated service with UK-licensed medications dispensed by qualified pharmacists. New patients can Save £20 on their first order using code Weightlossnew, making Wegovy injections accessible at the cheapest UK price without compromising on quality or clinical safety.

The ordering process is straightforward and discreet. Patients complete a free online consultation that takes under three minutes, covering medical history, current medications, and weight loss goals. Our UK-registered prescribers review each assessment individually, typically within hours, and approve treatment only when clinically appropriate. Once approved, Wegovy injections are dispensed from our UK pharmacy with discreet packaging and fast delivery options. Ongoing prescriptions can be managed through your online account, with regular follow-up consultations to monitor progress and ensure treatment remains suitable. For questions about Wegovy injections or the ordering process, our pharmacy team is available on (+44) 116 4646009.

Scientific References

1. Novo Nordisk. (2023). Wegovy (semaglutide) injection 2.4 mg: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 13 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & Lingvay, I. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE Technology Appraisal Guidance. [accessed 13 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.